Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HST-1011 |
| Synonyms | |
| Therapy Description |
HST-1011 inhibits CBLB, potentially resulting in increased anti-tumor immune response (Cancer Res 2023;83(8_Suppl):Abstract nr CT251). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HST-1011 | HST 1011|HST1011 | HST-1011 inhibits CBLB, potentially resulting in increased anti-tumor immune response (Cancer Res 2023;83(8_Suppl):Abstract nr CT251). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Active, not recruiting | USA | ESP | CAN | 0 |